239 related articles for article (PubMed ID: 15068800)
21. Structure of C3b in complex with CRIg gives insights into regulation of complement activation.
Wiesmann C; Katschke KJ; Yin J; Helmy KY; Steffek M; Fairbrother WJ; McCallum SA; Embuscado L; DeForge L; Hass PE; van Lookeren Campagne M
Nature; 2006 Nov; 444(7116):217-20. PubMed ID: 17051150
[TBL] [Abstract][Full Text] [Related]
22. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
23. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
24. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
26. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
27. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
28. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.
Rooijakkers SH; Ruyken M; Roos A; Daha MR; Presanis JS; Sim RB; van Wamel WJ; van Kessel KP; van Strijp JA
Nat Immunol; 2005 Sep; 6(9):920-7. PubMed ID: 16086019
[TBL] [Abstract][Full Text] [Related]
29. Structures of C3b in complex with factors B and D give insight into complement convertase formation.
Forneris F; Ricklin D; Wu J; Tzekou A; Wallace RS; Lambris JD; Gros P
Science; 2010 Dec; 330(6012):1816-20. PubMed ID: 21205667
[TBL] [Abstract][Full Text] [Related]
30. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
31. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of complement activation by crystalline cholesterol.
Vogt W; von Zabern I; Damerau B; Hesse D; Lühmann B; Nolte R
Mol Immunol; 1985 Feb; 22(2):101-6. PubMed ID: 3156272
[TBL] [Abstract][Full Text] [Related]
33. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
34. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
[TBL] [Abstract][Full Text] [Related]
35. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
36. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex.
Fishelson Z; Pangburn MK; Müller-Eberhard HJ
J Biol Chem; 1983 Jun; 258(12):7411-5. PubMed ID: 6553050
[TBL] [Abstract][Full Text] [Related]
37. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
38. The structure of complement C3b provides insights into complement activation and regulation.
Abdul Ajees A; Gunasekaran K; Volanakis JE; Narayana SV; Kotwal GJ; Murthy HM
Nature; 2006 Nov; 444(7116):221-5. PubMed ID: 17051152
[TBL] [Abstract][Full Text] [Related]
39. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
[TBL] [Abstract][Full Text] [Related]
40. Decay acceleration of the complement alternative pathway C3 convertase.
Hourcade DE; Mitchell LM; Medof ME
Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
